SENATE DOCKET, NO. 1780        FILED ON: 1/19/2023

SENATE  .  .  .  .  .  .  .  .  .  .  .  .  .  .  No. 1385

 

The Commonwealth of Massachusetts

_________________

PRESENTED BY:

John F. Keenan

_________________

To the Honorable Senate and House of Representatives of the Commonwealth of Massachusetts in General
Court assembled:

The undersigned legislators and/or citizens respectfully petition for the adoption of the accompanying bill:

An Act relative to collaborative drug therapy management optimization.

_______________

PETITION OF:

 

Name:

District/Address:

John F. Keenan

Norfolk and Plymouth


SENATE DOCKET, NO. 1780        FILED ON: 1/19/2023

SENATE  .  .  .  .  .  .  .  .  .  .  .  .  .  .  No. 1385

By Mr. Keenan, a petition (accompanied by bill, Senate, No. 1385) of John F. Keenan for legislation relative to collaborative drug therapy management optimization.  Public Health.

 

[SIMILAR MATTER FILED IN PREVIOUS SESSION
SEE SENATE, NO. 2492 OF 2021-2022.]

 

The Commonwealth of Massachusetts

 

_______________

In the One Hundred and Ninety-Third General Court
(2023-2024)

_______________

 

An Act relative to collaborative drug therapy management optimization.

 

Be it enacted by the Senate and House of Representatives in General Court assembled, and by the authority of the same, as follows:
 

Notwithstanding section 24 B1/2 of chapter 112 of the General Laws or any other general or special laws to the contrary, collaborative drug therapy management may be allowed in ambulatory care clinics licensed pursuant to section 51 of chapter 111 of the General Laws if: (i) there is on-site or off-site supervision by the attending physician and a collaborating pharmacist; and (ii) collaborative drug therapy management is approved by the ambulatory care clinic's medical staff executive committee or designee or medical director or designee.